Compass Therapeutics, Inc. (CMPX) Stock Score, Valuation & Financial Research

Compass Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for CMPX

Compass Therapeutics, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 1.00. These figures are a research snapshot, not a buy or sell recommendation.

What Compass Therapeutics, Inc. does

Compass Therapeutics, Inc. is a biopharmaceutical firm focused on developing cancer treatments, with several therapeutic candidates currently in clinical trials. The company's work involves creating antibody-based medicines designed to address a variety of human health conditions. Among its leading clinical-stage programs are CTX-009, an experimental bispecific antibody engineered to inhibit the Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, both of which are crucial for the growth of new blood vessels and tumor vascularization. Another significant compound is CTX-471, an IgG4 monoclonal antibody that functions as an activator of CD137. Furthermore, their developmental pipeline features CTX-8371, a bispecific inhibitor that targets both PD-1 and PD-L1. The company was established in 2014 and operates from its headquarters in Boston, Massachusetts.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Compass Therapeutics is a clinical-stage biopharmaceutical company that does not currently have any products approved for sale and has not generated any revenue from product sales. The company focuses on the research and development of proprietary antibody-based therapeutics for the treatment of solid tumor cancers and other human diseases, relying on capital raises and potential future licensing or collaboration agreements to fund its operations.

Products and services

  • The company is developing a pipeline of antibody-based therapeutics, including its lead clinical candidate, tovecimig, which is being studied for the treatment of solid tumors.

Customer types

Clinical trial patients.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of its clinical trial materials; specific supplier names are not disclosed. Source

Business relationships and partnerships

  • Handok — A collaboration partner that completed a Phase 2 clinical trial of tovecimig in combination with paclitaxel in patients with biliary tract cancer. Source

Business strengths to evaluate

  • Proprietary antibody-based therapeutic platform Source

Business risks and research considerations

  • History of operating losses and no revenue from product sales Source
  • Dependence on third-party manufacturers for clinical supply Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

CMPX financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 1.00
Market capitalization:
179.75M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -73.45M
Free cash flow:
USD -49.17M
Cash:
USD 35.45M
Total debt:
USD 9.63M
EPS:
USD -0.42

What stands out

  • Free cash flow is USD -49.17M, negative for the stored period.
  • The balance sheet shows USD 35.45M of cash versus USD 9.63M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 25.82M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for CMPX

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can CMPX fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is CMPX likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for CMPX to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of CMPX's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research CMPX

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.